Failure to Cure Patients with Colorectal Liver Metastases: The Impact of the Liver Surgeon

被引:16
作者
Vega, Eduardo A. [1 ]
Salehi, Omid [1 ]
Nicolausco, Diana [2 ]
Dussom, Edward-Michael [1 ]
Alarcon, Sylvia V. [3 ]
Kozyreva, Olga [3 ]
Simonds, Jana [1 ]
Schnipper, Deborah [1 ]
Conrad, Claudius [1 ]
机构
[1] Tufts Univ, Sch Med, St Elizabeths Med Ctr, Dept Surg, Boston, MA 02111 USA
[2] IOSUD Titu Maiorescu Univ Bucharest, Med Doctoral Sch, Tulcea Emergency Hosp, Bucharest, Romania
[3] Harvard Med Sch, Dana Farber Canc Inst, Boston, MA 02115 USA
关键词
D O I
10.1245/s10434-021-10030-0
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Lack of a liver surgeon (LS) may lead to failure to cure in patients with possibly resectable colorectal liver metastases (CRLM). This study aims to quantify the failure-to-cure rate due to noninclusion of an LS. Patients and Methods All patients who underwent chemotherapy with palliative intent for CRLM at a community oncology network between 2010 and 2018 were identified from a prospectively maintained cancer registry. Two LS blinded to patient management and outcome reviewed pretreatment imaging and assigned each scan a newly developed resectability score. Nominal group technique and independent scores were combined to determine probability of curative-intent resection. Interobserver agreement was calculated using kappa testing. Results This study included 72 palliative CRLM patients. Demographic factors were: 44 (59%) male, median age 68 years (range 36-94 years), 23 (32%) rectal primary, 24 (33%) receiving oxaliplatin-based chemotherapy. Of the 72 patients with CRLM, 6 had left-sided metastases only. The median number of CRLM was 6 (1-8). Agreement on resectability was achieved in 32 (44%) patients for the entire cohort and 17 (54%) in patients without extrahepatic disease. A lower median number of CRLM was found in the group considered to be resectable by the two LS (2 versus 8; p = 0.001). Substantial agreement was found between liver surgeons in the group of patients without extrahepatic disease (kappa = 0.9043). Conclusions Over 44% of patients who were assigned palliative chemotherapy at tumor boards without an LS were considered potentially resectable upon independent LS review.
引用
收藏
页码:7698 / 7706
页数:9
相关论文
共 53 条
[1]  
Adam R, 2004, ANN SURG, V240, P644, DOI 10.1097/01.sla.0000141198.92114.16
[2]  
Adam R, 2001, ANN SURG ONCOL, V8, P347
[3]   Two-stage hepatectomy: A planned strategy to treat irresectable liver tumors [J].
Adam, R ;
Laurent, A ;
Azoulay, D ;
Castaing, D ;
Bismuth, H .
ANNALS OF SURGERY, 2000, 232 (06) :777-784
[4]   Should a History of Extraperitoneal Disease Be a Contraindication to Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Colorectal Cancer Peritoneal Metastases? [J].
Baratti, Dario ;
Kusamura, Shigeki ;
Iusco, Domenico ;
Cotsoglou, Christian ;
Guaglio, Marcello ;
Battaglia, Luigi ;
Virzi, Salvatore ;
Mazzaferro, Vincenzo ;
Deraco, Marcello .
DISEASES OF THE COLON & RECTUM, 2018, 61 (09) :1026-1034
[5]   Pathologic Response to Preoperative Chemotherapy: A New Outcome End Point After Resection of Hepatic Colorectal Metastases [J].
Blazer, Dan G., III ;
Kishi, Yoji ;
Maru, Dipen M. ;
Kopetz, Scott ;
Chun, Yun Shin ;
Overman, Michael J. ;
Fogelman, David ;
Eng, Cathy ;
Chang, David Z. ;
Wang, Huamin ;
Zorzi, Daria ;
Ribero, Dario ;
Ellis, Lee M. ;
Glover, Katrina Y. ;
Wolff, Robert A. ;
Curley, Steven A. ;
Abdalla, Eddie K. ;
Vauthey, Jean-Nicolas .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (33) :5344-5351
[6]   Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study [J].
Bokemeyer, C. ;
Bondarenko, I. ;
Hartmann, J. T. ;
de Braud, F. ;
Schuch, G. ;
Zubel, A. ;
Celik, I. ;
Schlichting, M. ;
Koralewski, P. .
ANNALS OF ONCOLOGY, 2011, 22 (07) :1535-1546
[7]   Role of Neoadjuvant Chemotherapy in Resectable Synchronous Colorectal Liver Metastasis; an International Multi-Center Data Analysis Using Livermetsurvey [J].
Bonney, Glenn K. ;
Coldham, Chris ;
Adam, Rene ;
Kaiser, Gernot ;
Barroso, Eduardo ;
Capussotti, Lorenzo ;
Laurent, Christophe ;
Verhoef, Cees ;
Nuzzo, Gennaro ;
Elias, Dominique ;
Lapointe, Real ;
Hubert, Catherine ;
Lopez-Ben, Santiago ;
Krawczyk, Marek ;
Mirza, Darius F. .
JOURNAL OF SURGICAL ONCOLOGY, 2015, 111 (06) :716-724
[8]   High Survival Rate After Two-Stage Resection of Advanced Colorectal Liver Metastases: Response-Based Selection and Complete Resection Define Outcome [J].
Brouquet, Antoine ;
Abdalla, Eddie K. ;
Kopetz, Scott ;
Garrett, Christopher R. ;
Overman, Michael J. ;
Eng, Cathy ;
Andreou, Andreas ;
Loyer, Evelyne M. ;
Madoff, David C. ;
Curley, Steven A. ;
Vauthey, Jean-Nicolas .
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (08) :1083-1090
[9]   RAS Mutation Clinical Risk Score to Predict Survival After Resection of Colorectal Liver Metastases [J].
Brudvik, Kristoffer W. ;
Jones, Robert P. ;
Giuliante, Felice ;
Shindoh, Junichi ;
Passot, Guillaume ;
Chung, Michael H. ;
Song, Juhee ;
Li, Liang ;
Dagenborg, Vegar J. ;
Fretland, Asmund A. ;
Rosok, Bard ;
De Rose, Agostino M. ;
Ardito, Francesco ;
Edwin, Bjorn ;
Panettieri, Elena ;
Larocca, Luigi M. ;
Yamashita, Suguru ;
Conrad, Claudius ;
Aloia, Thomas A. ;
Poston, Graeme J. ;
Bjornbeth, Bjorn A. ;
Vauthey, Jean-Nicolas .
ANNALS OF SURGERY, 2019, 269 (01) :120-126
[10]   Ablation of colorectal liver metastasis: Interaction of ablation margins and RAS mutation profiling on local tumour progression-free survival [J].
Calandri, Marco ;
Yamashita, Suguru ;
Gazzera, Carlo ;
Fonio, Paolo ;
Veltri, Andrea ;
Bustreo, Sara ;
Sheth, Rahul A. ;
Yevich, Steven M. ;
Vauthey, Jean-Nicolas ;
Odisio, Bruno C. .
EUROPEAN RADIOLOGY, 2018, 28 (07) :2727-2734